Target-specific oral anticoagulants
Document Type
Article
Publication Date
1-1-2014
Abstract
Although for decades warfarin has been the gold standard for prevention of thromboembolic events, management is complicated by the drug's relatively narrow therapeutic window and the high incidence of interactions. Target-specific oral anticoagulants (TSOAs) are an attractive alternative to warfarin because they do not require routine monitoring and are associated with a low number of clinically relevant drug interactions. TSOAs include dabigatran, apixaban, and rivaroxaban. Pharmacology, dosing, clinical efficacy, and special considerations for these TSOAs are reviewed.
Recommended Citation
Ricchetti, Charlotte and Shea, Leticia, "Target-specific oral anticoagulants" (2014). Regis University Faculty Publications (comprehensive list). 660.
https://epublications.regis.edu/facultypubs/660